Bivigam® (immune globulin intravenous [human]) – Expanded indication
December 12, 2023, ADMA Biologics announced the FDA approval of Bivigam (immune globulin intravenous [human]), for the treatment of adults and pediatric patients 2 years of age and older with primary humoral immunodeficiency (PI).
Download PDF
